Genzyme GENZ

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. BRIEF-Ablynx enters into research collaboration with Genzyme

      Headlines

      Mon, 18 May 2015

      * Today announced that it has entered into an exclusive research collaboration with Genzyme , a Sanofi company

    2. Sanofi Posts Steady 1Q as Diverse Operating Platforms Help Offset Diabetes Weakness

      Commentary

      Thu, 30 Apr 2015

      Nordisk and Eli Lilly intensifies. Offsetting the diabetes pressures, strong innovation in the rare disease division Genzyme and brand power in consumer and animal health helped buoy the quarter. Recently launched drugs in multiple sclerosis

    3. BRIEF-Sanofi to present new data from Lemtrada clinical development

      Headlines

      Thu, 23 Apr 2015

      * Says effect of Genzyme 's multiple sclerosis treatment Lemtrada (alemtuzumab) on slowing brain atrophy and MRI lesion activity has been maintained through four years

    4. Sanofi Shakes Off Patent Losses

      Headlines

      Mon, 24 Nov 2014

      acquisitions are likely to slow in the near term following the Genzyme deal, we expect that over the long term Sanofi will continue ..... Viehbacher executed several acquisitions (such as Merial and Genzyme ) to create favorable returns on the capital deployed

    5. Sanofi's Board of Directors Ousts CEO, Leading to Stewardship Downgrade; No Change to Fair Value

      Commentary

      Wed, 29 Oct 2014

      strategic decisions made during his tenure. For example, Viehbacher executed several acquisitions (such as Merial and Genzyme ) to create favorable returns on the capital deployed. Nevertheless, the board's continued commitment to Sanofi's

    6. ClearBridge Fund Prepared for Extended Rally

      Video Reports

      Fri, 11 Oct 2013

      continues. I think there is going to be a theme, which we've seen in our portfolio, where historically names like Genzyme , Chiron, Millennium, and ImClone have all been acquired, and what we're seeing today is Big Pharma continue to chase

      Genzyme found at 3:20

      a theme, which we've seen in our portfolio, where historically names like Genzyme , Chiron, Millennium, and ImClone have all been acquired, and what we're seeing today is Big Pharma continue to chase growth and do
    7. Invest With These Exemplary Management Teams

      Headlines

      Sun, 26 May 2013

      the Medley, Chattem, Merial, and Genzyme acquisitions all have generated returns ..... than four years. Additionally, the Genzyme acquisition shows how Sanofi avoided ..... value rights, or CVR, to appease Genzyme . Further, Viehbacher's decision

    8. Sanofi's 4Q and 2013 Guidance Match Our Projections but Fall Short of Consensus Expectations

      Commentary

      Thu, 7 Feb 2013

      quarterly results. The company's updated guidance on an improving pipeline along with steady growth from emerging markets, Genzyme products, consumer health, vaccines, and diabetes drugs increases our conviction behind our wide moat rating for the

    9. Sanofi Posts Solid 3Q Supported by Cost-Containment Efforts, but No Change to Valuation

      Commentary

      Thu, 25 Oct 2012

      growth continued to perform well, with particular strength from diabetes drug Lantus, which was up 18% year over year. Genzyme products and emerging markets also continued to post steady gains. However, generic competition to cardiovascular drug

    10. LabCorp Adds to its Reference Lab Network with Medtox Scientific

      Commentary

      Tue, 5 Jun 2012

      challenging macroeconomic conditions. LabCorp's purchases of Genzyme Genetics' diagnostics unit and Orchid Cellmark in 2010 ..... times sales for Medtox, and it paid 2.5 times sales for Genzyme 's diagnostics in 2010--considerably lower compared

    « Prev12345Next »
    Content Partners